What are the limitations of current research on cannabis and migraines?

PostedFebruary 18, 2026

UpdatedFebruary 18, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

As interest grows in cannabis for migraine treatment, it’s important to examine the limitations of cannabis migraine research. While early findings are promising, current studies often face design flaws, small sample sizes, and inconsistent dosing, all of which affect the reliability of outcomes.

Understanding the limitations of cannabis migraine research helps patients and clinicians interpret findings more realistically. It also highlights where future work must focus to improve the overall quality of migraine and cannabis evidence limits.

Key Limitations in Current Studies

Despite growing interest, many scientific efforts still struggle with common barriers that limit progress.

Lack of large-scale clinical trials

Many findings are based on small observational studies or retrospective surveys. Without randomised trials, the cannabis and migraine study gaps remain significant.

Inconsistent cannabis formulations

Different THC:CBD ratios and consumption methods make it hard to compare results across studies. Standardisation is crucial for future accuracy.

Legal and regulatory hurdles

Research is often slowed or restricted by national laws, making it difficult for scientists to access high-quality cannabis. These cannabis research challenges affect study design and scope.

Limited long-term safety data

Most current studies focus on short-term relief. There is still little known about long-term use, dependency risks, or interactions with other treatments.

By acknowledging the limitations of cannabis migraine research, the medical community can push for more rigorous trials and better regulation. Addressing these cannabis and migraine study gaps is essential for developing safe, effective, and evidence-based treatment strategies.

If you’re exploring cannabis treatment options for migraines, visit providers like LeafEase for personalised consultations and guidance tailored to your needs.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and migraines.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.